Abstract
Introduction
The main function of pancreatic ␤ cells is to synthesize and secrete insulin at appropriate rates to limit blood glucose fluctuations. Excessive secretion of insulin causes hypoglycemia, and insufficient secretion leads to diabetes [1] . Therefore, it is not surprising that insulin secretion is subject to very tight control to ensure glucose homeostasis in the body. Insulin is stored in secretory granules in pancreatic ␤ cells and, upon stimulation with secretagogues, is released by exocytosis [2] . The level of ␤-cell activity is determined by several different stimulators, including glucose, amino acids, fatty acids, neurotransmitters and hormones. In spite of intensive studies, the processes that are involved in this stimulus-secretion coupling and that maintain exquisite control of insulin release are still incompletely understood [1, [3] [4] [5] . [8] . EGF can also induce secretion events, including acrosomal exocytosis and the secretion of several hormones [9, 10] . Some members of the EGF family are proposed to have a role in the development of the pancreas. EGF and leukemia inhibitory factor (LIF) treatment in vitro generated an insulin-producing ␤-cell mass [11] . The epidermal growth factor receptor (EGFR) is expressed throughout the human foetal pancreas, and mice lacking EGFR show abnormal pancreatic islets [12] . EGF is also related to the insulin content and regeneration of rat pancreatic ␤ cells. [13] [14] [15] . EGF is also produced in the pancreas, and its circulating levels, along with EGFR, are reduced in diabetic animals [6, 7, 16] . However [17] . PA is an intracellular lipid second messenger that is involved in multiple physiological events. These findings suggest that agonist-induced PLD activation may play roles in multiple signalling events [18, 19] . To date, two types of mammalian PLD, PLD1 and PLD2, have been cloned. They share a sequence homology of around 50% and contain similar regulatory domains. However, they show differences in localization and regulatory protein interactions [20] . PLD activity may be involved in various trafficking processes, particularly in the regulation of exocytosis [18] . PLD1 and PLD2 regulate different phases of exocytosis in mast cells by a two-step process [21] . In addition, PA is an important mediator of insulin exocytosis [22] . However, the specific regulation of PLDs by secretagogues remains unclear. Interestingly, PLD activity is inhibited in diabetic animals [23] . Therefore [24] . A PLD2-specific antibody was generated as described previously [25] . All other chemicals were purchased from Sigma (St. Louis, MO, USA). 
Epidermal growth factor (EGF) is an important growth factor for the proliferation of different types of cells, especially fibroblasts and epithelial cells
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EGF stimulates insulin secretion in MIN6 cells
EGF is produced in the pancreas and has pancreatic effects, and its circulating levels are altered in diabetes [6, 7] . [12] . Moreover, the effect of EGF on the release of insulin is quite rapid, and clearly detectable after 1 min. [18, 21, 22] . Furthermore, EGF is a strong agonist of PLD in various cells [29] [30] [31] . To investigate this, we first tested the PLD activity in MIN6 cells. PLD was rapidly activated (within 2 min.) by EGF stimulation (Fig. 3A) . [32] . In contrast, PLD2 exclusively mediated EGF-dependent insulin secretion, and over-expression of PLD1 showed a limited effect (Fig. 3C) . Furthermore, silencing of PLD2, but not PLD1, abolished EGF-induced insulin secretion (Fig. 3E) Fig. 3D and F Fig. 3C and D) or siRNAs (control (luciferase), mouse PLD1 or mouse PLD2 in Fig. 3E and F Fig. 3C and D) and PLD1 (inner boxes of Fig. 3E and F) , PLD2-specific antibody (inner boxes of Fig. 3E and F Fig. 6C and D) . Taken together, we conclude that EGF has the ability to stimulate insulin secretion and lower plasma glucose in normal and diabetic mice models. (Fig. 7) . nutrients, neurotransmitters and hormones, affect these processes [1, 2] . In this study, for the first time we show that EGF is a novel secretagogue that regulates plasma glucose levels, and determine the mechanism of EGF-induced insulin secretion. Type 2 diabetes mellitus is characterized by both insulin resistance and impaired insulin secretion. The control of insulin secretion is primarily regulated by glucose itself, but also involves an array of metabolic, neural, hormonal and sometimes pharmacologic factors [1, 33] . Initiators can increase insulin secretion in the absence of other stimulation, but potentiators require the presence of an initiator, usually glucose [1] . Many growth factors are also secreted from the pancreas or affect the pancreas, and their levels are often changed in diabetes [34] [35] [36] . However, few studies have been conducted to assess about the role of growth factors in regulating plasma glucose or as insulin secretion initiators. EGF requires only brief exposure (1 min.) to stimulate insulin secretion (Fig. 1A) , and increases Ca 2ϩ levels when treated alone ( Fig. 2A) , which indicates that it can function as an initiator. Furthermore, EGF additively stimulates glucose-dependent insulin secretion (Fig. 1D) [30, 32] . The mechanism underlying EGF-mediated activation of PLD remains controversial [29] [30] [31] 39] . Among the potential mechanisms, EGF-dependent increases in Ca 2ϩ activate protein kinase C (PKC) and lead to PLD activation [40] . Another report suggested that a Ca 2ϩ influx is associated with the activation of PLD, and that PKC is involved in this process [41] . However, there have been limited studies related to the Ca 2ϩ -mediated PLD activation of specific isozymes. In the present study, we identified PLD2 as a Ca 2ϩ -dependent isozyme in the pancreatic ␤ cells using EGF treatment (Fig. 3C-F) . Although PLD1 and 2 share a sequence homology of around 50% and contain similar regulatory domains [20] , they show differences in localization and regulatory protein interactions [39, 42] . A previous report suggested that PLD1 and PLD2 regulate different (Fig. 3C-F [44, 45] [6, 46] . EGFR is expressed throughout the human foetal pancreas, and mice lacking EGFR showed abnormal formation of pancreatic islets [12] . Some members of the EGF family play a role in the development of the pancreas [11] . EGF regulates the insulin content of rat pancreatic ␤ cells as well as their regeneration [13] [14] [15] . Furthermore, EGF deficiency is associated with diabetes mellitus; in diabetic animals, EGF or EGFR levels are decreased in various organs or fluids, such as the liver, the submandibular gland, plasma and milk [7, 16, 47, 48] . Interestingly, levels of these proteins often recover after insulin curative treatment [48] , and EGF and insulin act synergistically during diabetic healing [49] . A recent report suggested that EGF can regulate glucose homeostasis [50] . They focused on the role of EGF in regulating the plasma glucagon levels depending on the presence of glucose, and observed this effect using an animal model. Furthermore, combination therapy with EGF and gastrin induced ␤-cell regeneration in rodents with chemically induced diabetes [15] . Therefore, this study focused on the plasma insulin levels based on the results from insulinoma cell lines and islets, and determined the mechanism of EGF-dependent insulin secretion. Consistent with our in vitro findings from MIN6 (Fig. 1) , RINm5F (data not shown) cell line and mouse pancreatic islets (Fig. 5) , which indicated that EGF could stimulate the release of insulin, we found that EGF increased plasma insulin levels and decreased plasma glucose levels in normal and even in diabetic mice (Fig. 6) . Furthermore, we observed that physiological EGF levels were increased by a glucose injection and decreased after a sequential insulin injection (Fig. 7) 
Therefore, it is important to determine if EGF regulates insulin secretion by acting directly through its own receptor. To address this question, the effect of blocking of EGFR on the EGF-induced secretion of insulin was examined. The EGFR blocker (AG1478) completely inhibited the EGF-induced insulin secretion (Fig. 1C). Therefore, EGF induces insulin secretion through its own receptor. In order to exclude the possible cross-talk between EGF and glucagon-like peptide-1 (Glp-1) signalling, the effect of blocking of the Glp-1 receptor on the EGF-induced secretion of insulin was examined. The Glp-1 receptor blocker (EXENDIN fragment 9-39) had no effect on the EGF-induced insulin secretion in MIN6 cells (Supplement Fig. 1). Therefore, EGF induces insulin secretion through its own receptor and not through Glp-1 cross-talk. To determine whether insulin secretion by EGF was additive by glucose treatment, we tested the effect of a high level (11 mM) of glucose on EGF-induced insulin secretion. EGF increased insulin levels at a basal concentration of glucose (2.7 mM), and also additively increased glucose-induced insulin release at high (11 mM) glucose levels (Fig. 1D). Taken together, these data suggest that EGF, like glucose, is an initiator of insulin secretion in pancreatic ␤ cells, and also indicate that the effect of EGF on insulin secretion is glucoseindependent.
EGF-induced insulin secretion is dependent on Ca21 influx in MIN6 cells
Insulin secretion requires increases in intracellular Ca
PLD2 mediates EGF-dependent insulin secretion in MIN6 cells
Previous reports have suggested that PLD is an important molecule that mediates various exocytosis
EGF-dependent insulin secretion was inhibited by treatment with 1-butanol, a PLD inhibitor, but not by t-butanol treatment as a control (Fig. 3B). These results suggest that PLD activity is necessary for EGF-induced insulin secretion. The same results were also observed in RINm5F cells (data not shown).
. The same results were also observed in RINm5F cells (data not shown). Finally, EGF-dependent PLD activity, as measured with PBt formation, was modulated exclusively by PLD2 overexpression or silencing (
compared with EGFtreated cells. (C-F) The MIN6 cells were plated onto 24-well plates (for measuring insulin levels) or 6-well plates (for measuring PLD activity) and transfected with the indicated plasmids (vector, PLD1, or PLD2 in
1% Triton X-100 and subjected to SDS-PAGE, and were then immunoblotted using anti-PLDs antibody (inner boxes of
) or actin antibody (inner boxes of Fig. 3C-F). (A-F) The data shown are the mean Ϯ S.D. from two independent assays performed in duplicate. of mouse plasma glucose and insulin levels in normal and obese db/db mice by injecting EGF intravenously. In preliminary experiments, EGF (50 µg/kg) achieved a saturated plasma glucose-lowering effect 10 min. after intravenous injection into 7-to 8-weekold male ICR mice (data not shown). This glucose-lowering effect of EGF (50 µg/kg) had a similar potency to insulin and was dosedependent (Fig. 6A). Moreover, EGF increased plasma insulin levels (Fig. 6B), which suggests that this glucose-lowering effect is due to changes in plasma insulin levels. The kinetics of insulin secretion and changes in glucose were correlated. EGF also reduced plasma glucose in obese db/db mice and increased plasma insulin levels (
Glucose increases plasma EGF levels
EGF can regulate glucose homeostasis. Therefore, it is possible that the EGF levels in the body can be regulated by the feeding condition. Glucose was injected intravenously into 7-to 8-week-old male ICR mice and the plasma EGF levels were measured
Twenty minutes after the glucose injection, the plasma EGF levels were elevated. Because glucose stimulates EGF and insulin secretion, it is possible that if insulin level is increased and thereby glucose level is reduced, the opposite effect will be observed on EGF concentration. To test this hypothesis, insulin was injected intravenously 20 min. after the intravenous glucose injection. The results were compared with those from the intravenous saline injection. As a result, the insulin injection significantly attenuated the increase in EGF elevation caused by glucose (Fig. 7). In addition, an oral injection of glucose had the same effect of plasma EGF elevation (data not shown). This suggests that the physiological concentration of EGF can be altered by the feeding conditions, and secreted EGF finally regulates insulin secretion. Although the exact source of secreted EGF is not known, it can be assumed that this increase in plasma EGF
